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Abstract. Background: The effects of the bisphosphonate
derivative zoledronic acid (ZA) on the circulating levels of matrix
metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9
(MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen
activator (uPA) in patients with bone metastasis (BMTS) and the
possible correlation with the symptomatic response induced by this
drug in these patients were evaluated. Patients and Methods:
Proteinase levels were determined by enzyme-linked
immunosorbent assay (ELISA) in the plasma of 30 patients with
painful bone metastases from breast or prostate cancer undergoing
multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy
subjects (HS) of both genders (12 female and 30 male) served as
the control group. The symptomatic response to ZA was assessed
by the visual analog scale score (VAS). Results: The median
MMP-2 and MMP-9 pretreatment levels were more elevated in
BMTS as compared to HS (p≤0.0001). Conversely, uPA levels
were lower in BMTS p=0.0033; no significant difference was
observed for Cath B. ZA administration was associated with a
symptomatic response (VAS score≤4) in 25/30 patients (83.3%)
(p<0.0001). This phenomenon paralleled a decrease of Cath B
and MMP-2 plasma concentrations from baseline values on week
12 (p=0.05). A similar trend, although not statistically significant,
was also noted for MMP-9 and uPA. However, no direct
relationship was observed between the analgesic effect induced by
ZA and changes in the circulating levels of these enzymes.
Conclusion: These data show that ZA administration may
provide relief from bone pain in patients with diffuse skeletal
metastases and confirm a possible implication of cysteine
proteinases and matrix metalloproteinases in bone metastasis
formation, but not in the pathogenesis of metastatic bone pain.
Zoledronic acid (ZA) is new potent inhibitor of osteoclast-
mediated bone resorption, currently used for the palliative
treatment of tumor-associated osteolysis and hypercalcemia
(1). Interestingly, recent studies have highlighted that, in
addition to its anti-osteoclastic activity, ZA may affect tumor
cell growth and metastasis (1, 2). The specific mechanism(s)
underlying these effects are currently under investigation (1,
2). In this context, several studies have shown that this agent
may decrease the invasive potential of human breast and
prostate carcinoma cells in vitro and that this phenomenon
appears to be, at least in part, due to the inhibiting effects of
this drug on the activity of some proteinases involved in bone
metastasis formation, namely, matrix metalloproteinases-2
(MMP-2) and matrix metalloproteinase-9 (MMP-9) (3-5).
Moreover, recent clinical investigations have revealed that the
administration of ZA to cancer patients may also relieve the
pain associated with bone metastases (1, 6-9). These findings
suggest a possible correlation between the analgesic response
to ZA treatment and inhibition of MMP-2 and MMP-9
expression levels in tumor cells (1, 5-9). To test this hypothesis,
a pilot study was carried out to assess whether the
administration of ZA to patients with metastatic bone disease
(BMTS) alters the plasma levels of MMP-2 and MMP-9 and
those of two other main proteolytic enzymes implicated in the
metastatic process, namely cathepsin B (Cath B) and urokinase
type plasminogen activator (uPA) (10, 11), and whether these
alterations correlate with the analgesic response to ZA . 
Patients and Methods
The study were carried out on 30 consecutive patients with diffuse
skeletal metastases from breast or prostate cancer (Table I),
undergoing multiple treatment with zoledronic acid (Zometa®
Novartis, Basel, Switzerland, 4 mg i.v. by a 20-min infusion every 
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4 weeks). The patients were enrolled between January 2002 and
September 2004. The elegibility criteria included scintigraphic and
radiographic confirmation of bone metastasis, normal hepatic and
renal function, no chemotherapy for at least one month before ZA
treatment and pain not controlled by analgesic drugs (either FANS
or opioids). Patients receiving endocrine therapy were included if
under treatment for at least 3 months. Exclusion criteria were: i)
chemotherapy or radiation therapy within the previous 3 months,
ii) any previous bisphosphonate treatment, iii) the presence of
severe cardiovascular disease, refractory hypertension or
symptomatic coronary artery disease, iv) serum creatinine 
>3.0 mg/dL, v) serum calcium >8.0 mg/dL. All patients provided
written informed consent to the study, which was approved by the
local ethical committee and carried out in accordance with the
Declaration of Helsinki (12). The baseline evaluation consisted of
bone scan, skeletal X-ray, serum chemistry, complete blood cell
count, evaluation of serum tumor markers Ca15.3 and prostate
specific antigen (PSA) and that of some markers of bone
metabolism, namely bone alkaline phosphatase, c-telopeptide and
parathyroid hormone. The symptomatic response to ZA treatment
was assessed according to Serlin et al. (13) by using a visual analog
scale score (VAS), which ranged from 0 (no pain at all) to 10
(unbearable pain). A VAS score ≤4 was considered as an
acceptable analgesic response.
Cath B, MMP2, MMP9 and uPA plasma levels. Venous blood was
drawn into ethylenediammine tetra-acetic acid (EDTA)-coated tubes
just prior to ZA administration on day 0, week 4 and week 12. The
blood samples were centrifuged at 3,500 rpm for 15 min (Hereus
Omnifuge 2.0 RS, Hereus Sepatech). The plasma aliquots were
stored at –80ÆC until assays. Cath B, MMP-2, MMP-9 and uPA
concentrations were determined by commercially available enzyme-
linked immunosorbent assay (ELISAC) kits according to the
manufacturers’ instructions (Cath B ELISA kit, KrKa, Novo Mesto,
Slovenia; Biotrak MMP-2 and MMP-9 ELISA kits, Amersham
Bioscience, UK; IMUBIND uPA ELISA kit, product no. 894,
American Diagnostic, USA). The reported detection limits were 
0.9 ng/ml for CB, 0.37 ng/ml for MMP-2, 0.6 ng/ml for MMP-9 and 
10 pg/ml for uPA, respectively. Forty-two registered healthy blood
donors (HS) (30 male and 12 female, aged 19-62 years) were used as
the control group.
Statistical analysis. The statistical analysis was performed with the
Medcalc statistical software package version 7.4 (14). The data were
tested for normal distribution by the Kolmogorov-Smirnov test.
Because of their uneven distribution, statistical analysis was
performed, where required, by the non-parametric Mann-Withney
U-test, the Wilcoxon signed rank test or the Spearman rank
correlation test. The relationship between symptomatic response to
ZA treatments (VAS score trend) and the time-course variation of
proteinase plasma concentrations was evaluated by linear regression
analysis. The 0.05 level of probability was taken as significant. 
Results
The plasma distribution of MMP-2, MMP-9, Cath B and
uPA in healthy subjects (HS) and in patients with metastatic
bone disease (BMTS) is shown in Table II. No gender-
related differences were observed in the levels of any of
these proteolytic enzymes in HS (data not shown). The
median MMP-2 and MMP-9 concentrations prior to ZA
treatment were 2- to 4-fold higher in BMTS as compared to
HS (p<0.0001 and p=0.0001, respectively) (Table II).
Conversely, the Cath B and uPA concentrations were 1.5- to
2.0-fold lower in BMTS (Table II). However, this
phenomenon was statistically significant only in the case of
uPA (p=0.0033) (Table II). No substantial difference was
noted in the plasma level of these enzymes between patients
with bone metastases from breast cancer and those with
bone metastases from prostate cancer or between patients
with metastases confined only to the bones and those with
additional visceral metastases (data not shown). Among the
parameters considered, a positive correlation was highlighted
only between Cath B and MMP-9 basal values (r=0.556,
p=0.019). The administration of ZA was associated with a
significant symptomatic response in 25/30 patients (83.3%),
while no analgesic effect was seen in the other 5 patients
(16.7%). Furthermore, ZA administration induced a
significant decrease of Cath B and MMP-2 concentrations
from baseline values on week 12 (p=0.05) (Table III). A
similar phenomenon, although not statistically significant,
was also noted for MMP-9 and uPA (Table III). However,
significant fluctuations in uPA plasma levels were observed
between week 4 and week 12 (p=0.049) (Table III). Finally,
linear regression analysis did not show any significant
correlation between the time-course alteration of proteinase
levels and symptomatic response to ZA treatment (Cath
B:r=0.22, p=0.31; uPA:r= 0.23, p= 0.85; MMP-2: r= 0.06,
p=0.95; MMP-9: r = 0.97, p= 0.13) 
Discussion
The results of this pilot study indicated that patients with
diffuse skeletal metastases present a different pattern of
expression levels of some proteinases involved in tumor
progression. These findings further support the concept of a
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Table I. Patients’ characteristics (n=30).
Median age (range) 66.6 years 
(range 48-83)
Female/male 13/17
Median performance status ECOG score (range) 1 (0-2)
Tumor type:
Breast carcinoma 13
Prostate carcinoma 17
Metastasis:
bone only 18
bone + visceral 12
possible involvement of these enzymes in different steps of
bone metastasis formation (15). Thus, the lower levels of uPA
and Cath B in the plasma of patients with advanced
metastatic bone disease prior to ZA administration suggest
that these enzymes may be actively secreted in the early
phases of metastasis formation thereby facilitating the initial
steps of this phenomenon, such as the activation of growth
factors and that of the proteolytic cascade which triggers off
the metastatic process (15). Instead, the elevated levels of
MMP-2 and MMP-9 suggest that these proteinases may be
preferentially more secreted in subsequent steps and promote
later key events of bone metastasis formation, including
tumor cell-induced osteolysis (5, 8, 15-20). This may also,
partially, explain the positive correlation highlighted between
the baseline levels of Cath B and MMP-9. 
The administration of ZA to patients with bone
metastases was associated with a significant symptomatic
response which lasted throughout the observation period.
These findings further confirm our previous observations
and those of other studies (1, 6, 7-9). Interestingly, the
analgesic response to ZA treatment paralleled significant
changes in the plasma concentrations of Cath B and MMP-2
from the baseline values. A similar trend, although not
statistically significant, was also observed for MMP-9 and
uPA. However, these alterations do not seem to be due to a
direct growth inhibitory activity of this agent on metastatic
cells. This hypothesis is corroborated by the lack of clinical
evidence of antitumor response to ZA treatment in these
patients during the time-course of the study: evident. On the
other hand, proof of the direct antiproliferative effects of ZA
in vivo on bone metastatic cells in humans has still not been
provided. Because matrix metalloproteinases and cysteine
proteinases are actively secreted by osteoclasts during
normal and malignant remodeling processes of bone tissue
(1, 5, 8, 10, 16-24), it is probable that their altered levels may
be the result of the inhibiting effects of ZA on osteoclastic
activity. Therefore, the evaluation of the circulating levels of
these proteinases may be useful as additional biochemical
markers to monitor the clinical response of patients with
bone metastases treated with bisphosphonates. Nevertheless,
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Table II. Proteinase circulating levels in healthy subjects (HS) and in patients with bone metastases (BMTS).
HS (n=42) BMTS (n=30) % HS p valuea
Median (Range) Median (Range)
Cath B (ng/ml) 4.2 (0-26.8) 2.5 (0-19.2) –40.5% 0.28 (n.s.)
uPA (ng/ml) 1.09 (0.2-4.8) 0.43 (0.026-2.28) –60.6% 0.0033
MMP-2 (Ìg/ml) 0.75 (0.36-1.2) 1.46 (0.77-2.72) +194.6% <0.0001
MMP-9 (ng/ml) 29.4 (10.2-189.1) 101.7 (17.3-796.0) +345.9% 0.0001
aMann-Whitney U-test; n.s.= not significant
Table III. Time-course variation of VAS score and proteinase circulating levels in patients with metastatic bone disease treated with zoledronic acid (4
mg i.v. by a 20-min infusion every 4 weeks).
VAS score Cath B MMP-2 MMP-9 uPA
(ng/ml) (Ìg/ml) (ng/ml) (ng/ml)
Baseline 7.0 (9.0-3.0) 2.5 (0-19.2) 1.46 (0.77-2.72) 101.7 (17.3-796.0) 0.43 (0.026-2.28)
n=30a n=30 n=30 n=30 n=22
Week 4 4.0 (8.0-2.0)* 1.6 (0-21.3) 1.50 (1.03-2.78)¨ 59.05 (4.7-535) 0.60 (0-4.1)
n=30 n=22 n=30 n=30 n=22
Week 12 3.0 (7.0-2.0)*# 0 (0-5.6)ñ† 1.29 (1.12-2.06)ñ 43.5 (1.9-232.7) 0.31 (0-0.96)+
n=21a n=13 n=10 n=10 n=11
Data are expressed as median value and (range); Statistical analysis was computed by the Wilcoxon signed rank test.
aDue to some missing samples and/or patient follow-up, the number of evaluable subjects at each time-point may vary.
VAS *p<0.0001 vs. baseline and #p=0.012 vs. week 4; Cath B †p=0.048 vs. baseline and ñp=0.016 vs. week 4; MMP-2 ¨p=0.037 and ñp=0.05 vs.
baseline; uPA +p=0.049 vs. week 4.
the lack of a significant relationship between the analgesic
response and alteration of the proteinase plasma
concentrations following ZA administration seems to rule
out a direct involvement of these enzymes in the
pathogenesis of pain associated with skeletal metastasis. 
In summary, our data further demonstrate that multiple
ZA administrations may induce a significant symptomatic
response in patients with metastatic bone disease and
confirm a possible implication of cysteine proteinases and
matrix-metalloproteinases in bone metastasis formation, but
not in the pathogenesis of metastatic bone pain. 
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